Supercharged immune cells take on advanced melanoma in new trial
NCT ID NCT06961357
First seen Nov 12, 2025 · Last updated Apr 26, 2026 · Updated 20 times
Summary
This study tests whether immune cells taken from a patient's own tumor and boosted with a molecule called CD40L can shrink advanced melanoma. About 36 people with melanoma that has spread or cannot be removed, and who have not responded to standard treatments, will take part. Participants first receive chemotherapy to prepare their immune system, then a single infusion of the boosted cells, followed by a short course of interleukin-2 to support the cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Conditions
Explore the condition pages connected to this study.